In advanced EGFR-mutant NSCLC, gefitinib (12), and erlotinib (13) were the first TKIs to demonstrate improved progression free survival (PFS) in comparison with platinum doublet chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.